Back to Search
RALPH BOCCIA, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1881663284IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
D29675(MD)
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
D29675(MD)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
UNIVERSITY OF MINNESOTA MEDICAL SCHOOL
Class of 1977
Research & Publications (12)
The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
PMID 17522247·Oncologist·2007
3-trial
Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
PMID 16614237·Oncologist·2006
4-observational
Erythropoietic agents in chemotherapy-induced anemia: a review of recent therapeutic progress, issues, and concerns.
PMID 15496272·Curr Hematol Rep·2004
6-review
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
PMID 15337569·Int J Radiat Oncol Biol Phys·2004
6-review
Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
PMID 12577237·Semin Oncol·2002
6-review
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
PMID 19545290·Br J Haematol·2009
8-other
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
PMID 18829511·Clin Cancer Res·2008
3-trial
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
PMID 17010047·Br J Haematol·2006
3-trial
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
PMID 16710026·J Clin Oncol·2006
3-trial
A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
PMID 16187232·Breast Cancer Res Treat·2005
3-trial
Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
PMID 15658073·Am J Health Syst Pharm·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 6410 ROCKLEDGE DR, SUITE 660
BETHESDA, MD 20817 - Phone
- (301) 571-0019
Quick Facts
- NPI
- 1881663284
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 49
- Publications
- 12
Are you this provider?
Claim Your Profile